Literature DB >> 15661534

Hsp90 and Cdc37 -- a chaperone cancer conspiracy.

Laurence H Pearl1.   

Abstract

The Hsp90 molecular chaperone system is involved in the activation of an important set of cell regulatory proteins, including many whose disregulation drives cancer. Recruitment of protein kinases to the Hsp90 system is mediated by the co-chaperone adaptor Cdc37 -- an essential protein whose overexpression is itself, oncogenic. Current structural, biochemical and biological studies of Cdc37 are beginning to unravel the nature of its interactions with Hsp90 and protein kinase clients, and implicate it as a key permissive factor in cell transformation by disregulated protein kinases. The central role of the Hsp90-Cdc37 chaperone complex makes it an important target for future anti-cancer drug development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661534     DOI: 10.1016/j.gde.2004.12.011

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  102 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

Authors:  Hardik J Patel; Shanu Modi; Gabriela Chiosis; Tony Taldone
Journal:  Expert Opin Drug Discov       Date:  2011-05       Impact factor: 6.098

3.  Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.

Authors:  Yiqun Jiang; Denzil Bernard; Yanke Yu; Yehua Xie; Tao Zhang; Yanyan Li; Joseph P Burnett; Xueqi Fu; Shaomeng Wang; Duxin Sun
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

4.  Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.

Authors:  Asuka Ota; Jun Zhang; Peipei Ping; Jiahuai Han; Yibin Wang
Journal:  Circ Res       Date:  2010-03-18       Impact factor: 17.367

5.  The C-terminal domain of human Cdc37 studied by solution NMR.

Authors:  Ziming Zhang; Dimitra Keramisanou; Amit Dudhat; Michael Paré; Ioannis Gelis
Journal:  J Biomol NMR       Date:  2015-09-24       Impact factor: 2.835

Review 6.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

7.  The structure of CDK4/cyclin D3 has implications for models of CDK activation.

Authors:  T Takaki; A Echalier; N R Brown; T Hunt; J A Endicott; M E M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

8.  Bioactive metabolites from Chaetomium aureum: structure elucidation and inhibition of the Hsp90 machine chaperoning activity.

Authors:  Fatima Zahra Kabbaj; Su Lu; My El Abbés Faouzi; Bouchra Meddah; Peter Proksch; Yahya Cherrah; Hans-Josef Altenbach; Amal H Aly; Ahmed Chadli; Abdessamad Debbab
Journal:  Bioorg Med Chem       Date:  2014-11-20       Impact factor: 3.641

Review 9.  Cdc37 as a co-chaperone to Hsp90.

Authors:  Stuart K Calderwood
Journal:  Subcell Biochem       Date:  2015

10.  Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37.

Authors:  Yoshihiko Miyata; Eisuke Nishida
Journal:  Mol Cell Biochem       Date:  2008-06-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.